Compare CPRT & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPRT | INCY |
|---|---|---|
| Founded | 1982 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6B | 24.5B |
| IPO Year | 1996 | 1994 |
| Metric | CPRT | INCY |
|---|---|---|
| Price | $31.24 | $114.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 28 |
| Target Price | $39.00 | ★ $132.17 |
| AVG Volume (30 Days) | ★ 9.7M | 1.5M |
| Earning Date | 12-01-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | ★ 1.55 | 0.50 |
| Revenue | $1,805,695,000.00 | ★ $3,394,635,000.00 |
| Revenue This Year | $17.88 | $17.74 |
| Revenue Next Year | $12.05 | $4.38 |
| P/E Ratio | ★ $19.91 | $231.80 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $25.72 | $89.25 |
| 52 Week High | $41.79 | $132.60 |
| Indicator | CPRT | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 54.54 | 41.81 |
| Support Level | $29.97 | $109.78 |
| Resistance Level | $34.12 | $119.29 |
| Average True Range (ATR) | 0.87 | 3.73 |
| MACD | -0.15 | -0.53 |
| Stochastic Oscillator | 19.04 | 3.94 |
Based in Dallas, Copart operates a global online salvage-vehicle auction with operations in 11 countries across North America, Europe, and the Middle East, facilitating over 4 million transactions annually. The company utilizes its virtual bidding platform, VB3, to connect vehicle sellers with over 1 million registered buyers around the world. Buyers primarily consist of vehicle dismantlers, rebuilders, individuals, and used-vehicle retailers. About 80% of Copart's vehicle volume is supplied by auto insurance companies holding vehicles deemed a total loss. Copart also offers services such as vehicle transportation, storage, title transfer, and salvage value estimation. The company primarily operates on a consignment basis and collects fees based on the vehicle's final selling price.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.